Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC protocol 18781)
- 31 December 1993
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 29 (9), 1237-1242
- https://doi.org/10.1016/0959-8049(93)90064-m
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma.Journal of Clinical Oncology, 1991
- Long-Term Results of Intravesical Bacillus Calmette-Guerin Therapy for Superficial Bladder CancerJournal of Urology, 1989
- The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patientsCancer Immunology, Immunotherapy, 1989
- The process of metastasisCancer, 1985
- Metastatic malignant melanoma: Regression induced by combined treatment with interferon [HuIFN-α(Le)] and cimetidineInternational Journal of Cancer, 1983
- A Randomized Trial of Adjuvant Chemotherapy and Immunotherapy in Cutaneous MelanomaNew England Journal of Medicine, 1982
- A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I):Prognostic factors analysis and preliminary results of immunotheraypCancer, 1982
- Adjuvant reactivity predicts survival in patients with “high‐risk” primary malignant melanoma treated with systemic BCGInternational Journal of Cancer, 1981
- Adjuvant immunotherapy of high risk stage I melanoma with transfer factorCancer, 1981
- ACTIVE IMMUNOTHERAPY WITH B.C.G. FOR RECURRENT MALIGNANT MELANOMAThe Lancet, 1973